Clearmind rises after advancing trial of alcohol-use disorder drug

Clearmind Medicine

11/03/2026 13:21

** Shares of biotech company Clearmind Medicine CMND.O rise 10% to $1.10 premarket

** Co says it has begun enrolling participants in the third stage of its ongoing study for CMND‑100, an experimental drug for alcohol use disorder

** The condition is marked by difficulty controlling drinking despite harmful consequences; CMND‑100 aims to reduce cravings without causing hallucinations - CMND

** Co says move follows earlier studies showing the drug was safe and well‑tolerated

** Adds study sites include Yale University, Johns Hopkins University and Tel Aviv Sourasky Medical Center

** Shares fell ~97% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))